Clinical Trials at Lipella Pharmaceuticals

Hemorrhagic Cystitis Clinical Trial

Hemorrhagic Cystitis, also called Radiation Cystitis when occurring after pelvic radiation

Lipella recently completed a phase-2a, dose-escalation clinical trial evaluating LP-10 (liposomal tacrolimus) for the treatment of hemorrhagic cystitis. Results are published in the peer-reviewed journal, International Urology and Nephrology. Lipella has received US-FDA Orphan Designation for this product.

Radiation used to treat prostate, colon, uterine, cervical and other pelvic cancers can cause chronic, painful urinary inflammation and blood loss called hemorrhagic cystitis. The blood loss, associated with hemorrhagic cystitis and radiation cystitis can lead to surgery, and can be fatal.

Radiation Cystitis Patient Registry

If you are a cancer survivor with a history of pelvic radiation therapy, please consider joining the Radiation Cystitis Patient Registry.

Additional resources are needed to advance RC understanding – including the development of new and larger RC patient registries. The RC Foundation highlights the Radiation Cystitis Patient Registry, which aggregates data on the health status of individuals with RC.

The goal of the Radiation Cystitis Patient Registry is to create a resource to help doctors better recognize severe complications that arise long after pelvic radiation treatments. Researchers also use the Patient Registry to study RC treatments and outcomes and to design RC clinical trials.

Oral Lichen Planus Trial

Lipella was granted FDA approval to begin studying LP-310 in patients with oral lichen planus (OLP). This phase 2A multi-center, dose-escalation clinical trial will assess the safety and efficacy of LP-310 in patients with symptomatic OLP.